CRISPR/Cas-powered nanobiosensors for diagnostics.
Publication/Presentation Date
2-1-2022
Abstract
CRISPR diagnostics (CRISPR-Dx) offer a wide range of enhancements compared to traditional nanobiosensors by taking advantage of the excellent trans-cleavage activity of the CRISPR/Cas systems. However, the single-stranded DNA/RNA reporters of the current CRISPR-Dx suffer from poor stability and limited sensitivity, which make their application in complex biological environments difficult. In comparison, nanomaterials, especially metal nanoparticles, exhibits robust stability and desirable optical and electrocatalytical properties, which make them ideal as reporter molecules. Therefore, biosensing research is moving towards the use of the trans-cleavage activity of CRISPR/Cas effectors on metal nanoparticles and apply the new phenomenon to develop novel nanobiosensors to target various targets such as viral infections, genetic mutations and tumor biomarkers, by using different sensing methods, including, but not limited to fluorescence, luminescence resonance, colorimetric and electrochemical signal readout. In this review, we explore some of the most recent advances in the field of CRISPR-powered nanotechnological biosensors. Demonstrating high accuracy, sensitivity, selectivity and versatility, nanobiosensors along with CRISPR/Cas technology offer tremendous potential for next-generation diagnostics of multiple targets, especially at the point of care and without any target amplification.
Volume
197
First Page
113732
Last Page
113732
ISSN
1873-4235
Published In/Presented At
Phan, Q. A., Truong, L. B., Medina-Cruz, D., Dincer, C., & Mostafavi, E. (2022). CRISPR/Cas-powered nanobiosensors for diagnostics. Biosensors & bioelectronics, 197, 113732. https://doi.org/10.1016/j.bios.2021.113732
Disciplines
Medicine and Health Sciences
PubMedID
34741959
Department(s)
Medical Education
Document Type
Article